CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND AMENDMENT NO. 1 TO THE ROYALTY PURCHASE...Royalty Purchase Agreement • August 5th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
THIS AGREEMENT AND AMENDMENT NO. 1 (this “Amendment”) TO THE ROYALTY PURCHASE AGREEMENT, dated as of October 25, 2021 (the “Original Purchase Agreement”), is effective as of May 8, 2024 (the “Amendment Effective Date”) and is entered into by and between ANAPTYSBIO, INC., a Delaware corporation, as Seller (“Seller”), and SAGARD HEALTHCARE PARTNERS FUNDING BORROWER SPE 2, LP, a Delaware limited partnership (as assignee of Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership, which was, in turn, assignee of Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership), as Purchaser (“Purchaser”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the respective meanings ascribed to them in the Original Purchase Agreement (including as may be as ascribed to them in the License Agreement), except as otherwise set forth in Sections 2, 5 and 6 of this Amendment.
